HU-331

HU-331 is a quinone anticarcinogenic drug synthesized from cannabidiol, a cannabinoid in the Cannabis sativa plant. It showed high efficacy and potency in inhibiting the activity of topoisomerase II, a type of enzyme that modifies the topologic states of DNA during transcription. This compound has been found to be significantly less toxic than similar chemotherapy drugs, such as doxorubicin, but is not currently used in humans.

Chemistry

HU-331 is a quinone compound, which is a class of cyclic organic compounds with two carbonyl groups. It is synthesized from cannabidiol, a phytocannabinoid found in the Cannabis sativa plant. The synthesis process involves the oxidation of cannabidiol.

Pharmacology

HU-331 has been found to have anticarcinogenic properties. It works by inhibiting the enzyme topoisomerase II, which is involved in the replication of cancer cells. By inhibiting this enzyme, HU-331 can prevent the replication and spread of cancer cells.

Toxicity

In comparison to other chemotherapy drugs, such as doxorubicin, HU-331 has been found to be significantly less toxic. This could potentially make it a safer alternative for cancer treatment. However, more research is needed to fully understand its toxicity and safety profile.

Research

Research on HU-331 is still in the early stages. While it has shown promise in preclinical studies, it has not yet been tested in humans. Further research is needed to determine its efficacy and safety in human subjects.

See also

• Cannabidiol
• Cannabis sativa
• Topoisomerase II
• Quinone
• Anticarcinogen

HU-331 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia